Efficient siRNA-peptide conjugation for specific targeted delivery into tumor cells
Albert Gandioso1, Anna Massaguer2, Núria Villegas3
1Department of Inorganic and Organic Chemistry, Section of Organic Chemistry, IBUB, University of Barcelona, Martí i Franquès 1-11, 08028 Barcelona, Spain.
Summary
Researchers developed a simple method to attach peptides to small interfering RNAs (siRNAs). This peptide-siRNA functionalization enables targeted delivery into HER2-positive breast cancer cells.
Area of Science:
- Bioconjugation Chemistry
- RNA Therapeutics
- Cancer Cell Biology
Background:
- The Huisgen cycloaddition reaction is widely applicable but faces challenges in RNA-peptide functionalization.
- Efficiently attaching peptides to small interfering RNAs (siRNAs) is crucial for targeted drug delivery.
- Current methods for siRNA modification are often complex or inefficient.
Purpose of the Study:
- To develop a straightforward method for the click functionalization of siRNAs with peptides.
- To demonstrate the versatility of the method with peptides of varying sizes and complexities.
- To identify and report a peptide carrier for selective siRNA delivery into HER2-positive breast cancer cells.
Main Methods:
- Utilized the Huisgen cycloaddition reaction for efficient siRNA-peptide conjugation.
- Synthesized and characterized various peptide-siRNA conjugates.
- Evaluated the delivery efficiency of functionalized siRNAs into HER2-positive breast cancer cell lines.
Main Results:
- A facile and effective method for click functionalization of siRNAs with peptides was established.
- Peptides of diverse sizes and complexities were successfully conjugated to siRNAs.
- A specific peptide carrier demonstrated selective delivery of siRNA into HER2+ breast cancer cells.
Conclusions:
- The developed method provides a robust platform for creating peptide-siRNA conjugates.
- This approach overcomes previous limitations in RNA-peptide bioconjugation.
- The identified peptide carrier shows significant potential for targeted siRNA-based cancer therapy.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
59
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
59
Site-Targeted Drug Delivery Systems: Polymeric Carriers
67
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
67
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K


